These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22183059)

  • 21. Subjective rating of cosmetic treatment with botulinum toxin type A: do existing measures demonstrate interobserver validity?
    Conkling N; Bishawi M; Phillips BT; Bui DT; Khan SU; Dagum AB
    Ann Plast Surg; 2012 Oct; 69(4):350-5. PubMed ID: 22964674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
    Rivers JK; Bertucci V; McGillivray W; Muhn C; Rosen N; Solish N; Weichman BM; Wheeler S; Daniels SR; Gallagher CJ
    Dermatol Surg; 2015 Aug; 41(8):950-9. PubMed ID: 26218728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®) ) or abobotulinumtoxinA (Dysport(®) ) make a difference?
    Ravindra P; Jackson BL; Parkinson RJ
    BJU Int; 2013 Jul; 112(1):94-9. PubMed ID: 23490404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke.
    Dunne JW; Gracies JM; Hayes M; Zeman B; Singer BJ;
    Clin Rehabil; 2012 Sep; 26(9):787-97. PubMed ID: 22308557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin.
    Beer KR; Julius H; Dunn M; Wilson F
    J Cosmet Dermatol; 2014 Jun; 13(2):143-50. PubMed ID: 24910278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of IncobotulinumtoxinA for the treatment of platysmal bands of the aging neck: an open-label, prospective pilot study.
    Gubanova EI; Panova OS; Sanchez EA; Rodina MY; Starovatova PA
    J Drugs Dermatol; 2013 Dec; 12(12):1461-6. PubMed ID: 24301249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Prospective, Split-Face, Randomized, Double-Blind Study Comparing OnabotulinumtoxinA to IncobotulinumtoxinA for Upper Face Wrinkles.
    Yeilding RH; Fezza JP
    Plast Reconstr Surg; 2015 May; 135(5):1328-1335. PubMed ID: 25919246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
    Joseph JH; Eaton LL; Robinson J; Pontius A; Williams EF
    J Drugs Dermatol; 2016 Dec; 15(12):1544-1549. PubMed ID: 29106437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion of two botulinum toxins type A on the forehead: double-blinded, randomized, controlled study.
    Jiang HY; Chen S; Zhou J; Leung KK; Yu P
    Dermatol Surg; 2014 Feb; 40(2):184-92. PubMed ID: 24438121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
    De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
    Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.
    Ascher B; Rzany BJ; Grover R
    Dermatol Surg; 2009 Oct; 35(10):1478-86. PubMed ID: 19686365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of botulinum toxin type A in cosmetic facial procedures.
    Jaspers GW; Pijpe J; Jansma J
    Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
    Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
    Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials.
    Baumann L; Dayan S; Connolly S; Silverberg N; Lei X; Drinkwater A; Gallagher CJ
    Dermatol Surg; 2016 May; 42(5):598-607. PubMed ID: 27110893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
    Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of headache relief with cosmetic onabotulinumtoxinA injections.
    Goldman ND; Dorton LH; Marcum KK; Gilbert RM; Sandoval LF
    J Cosmet Dermatol; 2014 Sep; 13(3):224-31. PubMed ID: 25196690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, Patient-Reported Outcomes, and Safety in Male Subjects Treated With OnabotulinumtoxinA for Improvement of Moderate to Severe Horizontal Forehead Lines.
    Keaney TC; Cavallini M; Leys C; Rossi A; Drinkwater A; Manson Brown S; Garcia JK; Mao C
    Dermatol Surg; 2020 Feb; 46(2):229-239. PubMed ID: 31343446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
    Hexsel D; Brum C; do Prado DZ; Soirefmann M; Rotta FT; Dal'Forno T; Rodrigues TC
    J Am Acad Dermatol; 2012 Aug; 67(2):226-32. PubMed ID: 22041253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.